21.2 C
New York
Tuesday, June 9, 2026

Tag: cost reduction

newssourceFORcompanyinformationcontent1marketreleases

HYSTER-YALE ANNOUNCES SECOND QUARTER 2025 RESULTS

Q2 2025 Consolidated Highlights:  Consolidated revenues improved 5% from Q1 2025 to $957 millionOperating loss of $8.5 million and adjusted operating profit of $7.2 million...

JELD-WEN Reports Second Quarter 2025 Results and Reinstates Full Year Guidance

CHARLOTTE, N.C., Aug. 5, 2025 /PRNewswire/ -- JELD-WEN Holding, Inc. (NYSE: JELD) ("JELD-WEN" or the "Company") today announced results for the three and six...

Cryoport Reports Second Quarter 2025 Financial Results

Second quarter revenue increased 14% year-over-year to $45.5 millionCommercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 millionLife Sciences Services revenue rose...

Resideo Announces Record Second Quarter 2025 Financial Results; Raises 2025 Outlook; Initiates Third Quarter 2025 Outlook

Record high second quarter net revenue of $1.94 billion, up 22% year-over-year and above the high-end of outlook range; up 8% on an organic...

Opendoor Announces Second Quarter of 2025 Financial Results

SAN FRANCISCO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Opendoor Technologies Inc. (Nasdaq: OPEN), a leading e-commerce platform for residential real estate transactions, today reported financial results for its second quarter ended June 30, 2025. Opendoor’s second quarter 2025 financial results and management commentary can be accessed through the Company’s shareholder letter on the “Quarterly Reports” page of Opendoor’s investor relations website at https://investor.opendoor.com/financials-filings/quarterly-reports.

ArcheHealth Selects Amendola for Go-to-Market Program of its AI-Powered Healthcare Cost Reduction Solution

SCOTTSDALE, Ariz., Aug. 5, 2025 /PRNewswire/ -- Amendola, a nationally recognized, award-winning healthcare technology and life sciences public relations and marketing firm, announced ArcheHealth has...

The American Diabetes Association Marks 85 Years of Advancements in Diabetes Care and Discovery

ARLINGTON, Va., Aug. 5, 2025 /PRNewswire/ -- This month, the American Diabetes Association® (ADA) celebrates 85 years of dedicated work toward its vision of...

Reitmans (Canada) Limited Announces Approval of Normal Course Issuer Bid

MONTREAL, Aug. 1, 2025 /CNW/ - Reitmans (Canada) Limited ("RCL" or the "Company") (TSXV: RET) (TSXV: RET.A) today announces that it has received approval...

Lightspeed Announces First Quarter 2026 Financial Results

Total revenue in the quarter of $304.9 million grew 15% year-over-year and exceeded outlook Gross margin improved to 42%, with gross profit increasing 19% year-over-year exceeding...

Albemarle Reports Second Quarter 2025 Results

CHARLOTTE, N.C., July 30, 2025 /PRNewswire/ -- Albemarle Corporation (NYSE: ALB), a global leader in providing essential elements for mobility, energy, connectivity and health,...

22nd Century Applauds the American Academy of Family Physicians Comments and Support of the FDA’s Proposed Reduced Nicotine Mandate to Reduce Smoking, Transform Public...

22nd Century VLN® products are the only combustible cigarettes authorized by the FDA as a reduced nicotine content product that comply with the FDA proposed rule

Whirlpool Corporation Announces Second-Quarter Results

Delivered sequential net sales growth across all segments, despite negative consumer sentiment impacting global demandDelivered significant cost take out of 100 basis points or...

Olin Announces Second Quarter 2025 Results

Highlights Second quarter 2025 net loss of ($1.3) million, or ($0.01) per diluted shareQuarterly adjusted EBITDA of $176.1 millionSecond quarter 2025 operating cash flow of...

Q2 Sales and H1 2025 Financial Results

 

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCost reduction

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers